Akari Therapeutics (AKTX) Interim CFO Farag Receives RSU Award

What Happened
Kameel D. Farag, Interim Chief Financial Officer of Akari Therapeutics plc (AKTX), was granted 1,130 American Depositary Shares (ADS) recorded as an award on July 16, 2026. The grant is reported at $11.50 per ADS for a total reported value of $12,995. This transaction is an award/grant (code A), not an open‑market purchase or sale.

Key Details

• Transaction date: 2026-07-16; Form 4 filed: 2026-08-05. (Note: Form 4 was filed ~20 days after the transaction; the usual SEC deadline for Form 4 is 2 business days.)
• Quantity and price: 1,130 ADS @ $11.50 each = $12,995 reported value.
• Shares owned after the transaction: Not disclosed in the provided excerpt.
• Vesting/derivative note (from filing footnote): these ADS represent restricted stock units (RSUs); each RSU is stated to represent the right to receive 80,000 ordinary shares. The RSUs will vest in full on August 16, 2026.
• Transaction code: A = Award/Grant.

Context
This is a grant of restricted-equity (RSU-based ADS) to an executive and will vest on a future date; such awards are common as compensation and do not by themselves signal buying or selling intent. The footnote’s statement that each RSU represents the right to 80,000 ordinary shares is taken verbatim from the filing and implies a large underlying share multiplier; review the full Form 4 or company disclosures for clarification if this detail is material to your assessment.